Considering that the application of these antibodies is an already established therapy used to treat severe hypercholesterolemia with little adverse effects [27], peripheral PCSK9 inhibition could be a valuable tool to target cerebral Aβ accumulation in AD patients. Here, PCSK9 is linked to familial hypercholesterolemia.